Drug review provisions massively to reshuffle.

Published: 2005-09-07 06:57:00

Updated: 2005-09-07 06:57:00

Lawyer Park Jeong-il, a legal adviser for the KFDA, suggested his plans to reshuffle the relevant provisions of drug review in the meeting on the subject of the drug safety scheduled on Sept. 5.

The current provision describes that the drugs fallen under Article 26 paragraph 6 of the Working R...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK